Publications | Incyclix Bio

INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors

Catherine Dietrich^1,2, Alec Trub³, Antonio Ahn^1,2, Michael Taylor^1,2, Krutika Ambani^1,2, Keefe T. Chan^1,2,
Kun-Hui Lu^1,2, Christabella A. Mahendra^1,2, Catherine Blyth^1,2, Rhiannon Coulson^1,2, Susanne Ramm^1,2,
April C. Watt^1,2, Sunil Kumar Matsa⁴, John Bisi³, Jay Strum³, Patrick Roberts³, and Shom Goel^1,2

Cancer Discov 2024;14:446–67

See the Publication >

INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers

Alec G. Trub¹, John E. Bisi¹, Catherine Dietrich², Michael Taylor, Jay C. Strum¹, Shom Goel², Patrick J. Roberts¹
¹Incyclix Bio, Durham, NC, United States, ²The Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

See the Publication >